A possible explanation for this is that anti-CTLA-4 antibody suppresses cancer immunity through a mechanism different from anti-PD-1 or anti-PD-L1 antibodies by priming and activating tumor-specific T cells [13–15]; hence, it may affect tumors that have acquired resistance to PD-(L)1-targeted immunotherapy. Here, PDCD1 is linked to neoplasm.